• Türkçe
    • English
  • Türkçe 
    • Türkçe
    • English
  • Giriş
Öğe Göster 
  •   DSpace Ana Sayfası
  • Fakülteler
  • Eczacılık Fakültesi
  • Eczacılık Meslek Bilimleri Bölümü
  • Makale Koleksiyonu
  • Öğe Göster
  •   DSpace Ana Sayfası
  • Fakülteler
  • Eczacılık Fakültesi
  • Eczacılık Meslek Bilimleri Bölümü
  • Makale Koleksiyonu
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

Gilaburu (Viburnum opulus L.) fruit extract has potential therapeutic and prophylactic role in a rat model of acetic acid-induced oxidant colonic damage

Thumbnail

Göster/Aç

Tam Metin / Full Text (8.641Mb)

Tarih

2024

Yazar

Gülada, Begümhan Ömeroğlu
Çam, Muhammet Emin
Yüksel, Meral
Akakın, Dilek
Taşkın, Turgut
Emre, Gizem
Şener, Göksel
Karakoyun, Berna

Üst veri

Tüm öğe kaydını göster

Künye

Gülada, B. Ö.; Çam, M. E.; Yüksel, M.; Akakın, D.; Taşkın, T.; Emre, G.; Şener, G.; Karakoyun, B. Gilaburu (Viburnum opulus L.) fruit extract has potential therapeutic and prophylactic role in a rat model of acetic acid-induced oxidant colonic damage (2024). Journal of Ethnopharmacology, v.322, 117624.

Özet

Ethnopharmacological relevance: Ulcerative colitis (UC) which has a global impact on the health care system with its recurrent and incompletely curable characteristics, affects the patients’ quality of life. Gilaburu (GB; Viburnum opulus L.) is a fruit with rich polyphenol ingredient which is used ethnobotanically in Türkiye for medicinal purposes (for example, to pass kidney stones, to treat stomach, heart, and liver diseases, hemorrhages, hypertension, ulcers, common cold, tuberculosis, rheumatic and menstrual pain, and diabetes). On the other hand, the effects of GB in the experimental UC model have not been studied. Aim of the study: This study aimed to explore the potential antioxidant and anti-inflammatory effects of GB fruit extract in improving acetic acid (AA)-induced UC. Materials and methods: Starting immediately after (AA + GB group) or 1 week before (GB + AA + GB group) the colitis induced by intrarectal AA (5%; v/v) administration, the rats orally received GB (100 mg/kg) once per day for 3 days. The control and AA groups were administered orally saline (1 ml), while the AA + SS group were administered sulfasalazine (SS; 100 mg/kg; orally) as a positive control once per day for 3 days. Distal colonic tissue specimens were obtained for the histological and biochemical [myeloperoxidase (MPO), malondialdehyde (MDA), glutathione (GSH), chemiluminescence (CL), caspase-3, 8-hydroxy-2’-deoxyguanosine (8-OHdG), matrix metalloproteinase (MMP)-9, transforming growth factor (TGF)-β1, smad-3 and cytokine (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8, interferon (IFN)-γ), measurements] evaluations on the 3rd day. Results: Elevated macroscopic and microscopic damage scores, high tissue wet weight values, increased tissue-associated MPO, MDA, CL, caspase-3, 8-OHdG, cytokines (TNF-α, IL-1β, IL-6, IL-8), MMP-9, TGF-β1, smad-3 levels, and decreased GSH values of the AA group were all reversed by GB treatments (AA + GB and GB + AA + GB groups) (p < 0.05–0.001). However, sulfasalazine treatment (AA + SS group) did not change the IL-8, 8-OHdG, MMP-9, and TGF-β1 measurements significantly. Conclusions: Gilaburu shows both anti-inflammatory and antioxidant effects against AA-induced colonic damage by suppressing neutrophil infiltration, regulating inflammatory mediators, inhibiting reactive species production, lipid peroxidation, and apoptosis, conserving endogenous antioxidant glutathione, and ameliorating oxidative DNA damage. Since the current ulcerative colitis drugs display limited benefits and adverse side effects, potential therapeutic and/or prophylactic role of gilaburu can be evaluated in ulcerative colitis.

Kaynak

Journal of Ethnopharmacology

Cilt

322

Bağlantı

https://www.sciencedirect.com/science/article/pii/S0378874123014940?via%3Dihub
https://doi.org/10.1016/j.jep.2023.117624
https://pubmed.ncbi.nlm.nih.gov/38128893/
https://hdl.handle.net/20.500.12780/925

Koleksiyonlar

  • Makale Koleksiyonu [21]
  • PubMed İndeksli Yayınlar Koleksiyonu [158]
  • Scopus İndeksli Yayınlar Koleksiyonu [301]
  • WoS İndeksli Yayınlar Koleksiyonu [268]



DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 




| Yönerge | Rehber | İletişim |

DSpace@Kent

by OpenAIRE
Gelişmiş Arama

sherpa/romeo

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreDile GöreBölüme GöreKategoriye GöreYayıncıya GöreErişim ŞekliKurum Yazarına GöreBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreDile GöreBölüme GöreKategoriye GöreYayıncıya GöreErişim ŞekliKurum Yazarına Göre

Hesabım

GirişKayıt

DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 


|| Rehber || Yönerge || Kütüphane || İstanbul Kent Üniversitesi || OAI-PMH ||

İstanbul Kent Üniversitesi, İstanbul, Türkiye
İçerikte herhangi bir hata görürseniz, lütfen bildiriniz:

Creative Commons License
İstanbul Kent Üniversitesi Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Kent:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.